Velvin10 mg/10 ml

Velvin is a vinca alkaloid antineoplastic agent used, under the supervision of a qualified oncology specialist, for the treatment of the following malignancies:

Established / FDA-approved uses

• Hodgkin lymphoma - as part of combination chemotherapy regimens in patients who have relapsed or failed to respond to first-line therapy.
• Lymphocytic lymphoma (nodular or diffuse) - in patients resistant to other chemotherapeutic agents.
• Histiocytic lymphoma.
• Advanced-stage mycosis fungoides (cutaneous T-cell lymphoma).
• Advanced testicular germ cell cancer - as part of combination regimens (e.g. with bleomycin and cisplatin).
• Kaposi sarcoma.
• Letterer-Siwe disease (Langerhans cell histiocytosis) in children.

Uses generally requiring combination therapy or reserved for resistant disease

• Choriocarcinoma resistant to other chemotherapeutic agents.
• Breast cancer that has not responded adequately to appropriate endocrine surgery and hormonal therapy.

Velvin is almost always given as one component of a multi-drug chemotherapy protocol rather than as a single agent, and the choice of regimen is individualized by the treating oncologist based on disease stage, prior therapy, and patient status.

Each vial contains Vinblastine Sulfate equivalent to 10 mg of vinblastine, as a sterile powder or solution for intravenous injection after reconstitution/dilution as directed by the manufacturer.

Velvin is a naturally derived vinca alkaloid, obtained from the periwinkle plant Catharanthus roseus, formulated as a sterile injectable salt for intravenous chemotherapy use. It is classified as a cell-cycle-specific antineoplastic (mitotic inhibitor) and is used in the treatment of selected lymphomas, testicular cancer, Kaposi sarcoma, and certain other malignancies, typically as part of combination chemotherapy regimens.

Velvin is intended strictly for intravenous administration by, or under the direct supervision of, a physician experienced in the use of cancer chemotherapeutic agents. It carries a boxed warning because accidental intrathecal (spinal) administration is fatal.

Velvin belongs to the vinca alkaloid class of antineoplastic (anticancer) agents, a subgroup of mitotic inhibitors/plant alkaloid chemotherapy drugs.

Vinblastine Sulfate is a vinca alkaloid that exerts its cytotoxic effect primarily by binding to tubulin, a key structural protein of the mitotic spindle. This binding inhibits microtubule assembly, arresting dividing cells in metaphase (M-phase) of the cell cycle. As a result, mitosis is blocked and cells undergo apoptosis.

Vinblastine Sulfate is cell-cycle-phase specific, meaning it primarily affects rapidly dividing cells such as malignant cells, but also affects other rapidly dividing normal tissues (e.g. bone marrow, mucosa, hair follicles), which accounts for its characteristic toxicity profile (myelosuppression, mucositis, alopecia).

Pharmacokinetics: Following intravenous administration, Vinblastine Sulfate is extensively bound to plasma proteins and distributes into tissues; it is metabolized in the liver, largely via the CYP3A4 pathway, to active and inactive metabolites, and is eliminated mainly through biliary/fecal excretion, with only a small fraction excreted renally. Its terminal half-life is triphasic, with a prolonged terminal elimination phase.

Velvin is administered by slow intravenous injection or as a short intravenous infusion, through a securely placed IV line, by trained oncology staff only. It must NEVER be given intrathecally (into the spinal fluid), as this is fatal. Care must be taken to avoid extravasation into surrounding tissue.

The following clinically significant interactions should be considered when Velvin is prescribed:

• Strong CYP3A4 inhibitors (e.g. itraconazole, ketoconazole, ritonavir, clarithromycin): may increase plasma concentrations of Velvin, increasing the risk of neurotoxicity and other toxicities; use with caution and monitor closely, or avoid combination where possible.
• Phenytoin and other hepatically metabolized anticonvulsants: concurrent chemotherapy including Velvin can reduce phenytoin plasma levels, increasing the risk of seizures; anticonvulsant levels should be monitored and dosage adjusted as needed.
• Mitomycin C: concurrent or sequential use with Velvin has been associated with acute pulmonary reactions (acute shortness of breath and severe bronchospasm); patients receiving both drugs should be monitored closely.
• Other myelosuppressive drugs or radiation therapy: concurrent use with Velvin can increase the risk and severity of bone marrow suppression.
• Live vaccines: should generally be avoided during treatment with Velvin because of immunosuppression and the risk of disseminated vaccine-strain infection.

Adverse effects of Velvin are generally dose-related. Common and important adverse effects include:

• Bone marrow suppression (myelosuppression): leukopenia is the dose-limiting toxicity; regular complete blood counts are required and doses are adjusted based on the WBC nadir.
• Gastrointestinal: nausea, vomiting, constipation, abdominal pain, and in severe cases paralytic ileus.
• Neurological: peripheral neuropathy (numbness, tingling, weakness), jaw pain, loss of deep tendon reflexes - generally less frequent/severe than with vincristine but still reported.
• Alopecia (hair loss), usually reversible after treatment ends.
• Local reactions: pain, phlebitis, and severe tissue necrosis/cellulitis if extravasation occurs during administration.
• Other: mucositis/stomatitis, malaise, weakness, hypertension, and, rarely, syndrome of inappropriate antidiuretic hormone secretion (SIADH).

Velvin can cause fetal harm when administered to a pregnant woman, based on its mechanism of action and animal reproduction data. Velvin should be used during pregnancy only if the potential benefit to the mother clearly justifies the potential risk to the fetus, and only under the close supervision of an oncologist; women of reproductive potential should be advised of the potential hazard to the fetus and effective contraception should be used during and for a period after treatment.

It is not known whether Velvin is excreted in human breast milk; because of the potential for serious adverse effects in nursing infants, breastfeeding should be discontinued during treatment with Velvin. Consult a physician before use in pregnancy or while breastfeeding.

Boxed Warning - Fatal if given intrathecally

Velvin is for intravenous use ONLY. Accidental intrathecal (spinal) administration of vinca alkaloids such as Velvin is fatal, causing ascending paralysis and death. Institutions must have strict administration protocols in place, including clear labeling that the syringe/infusion bag contents are for intravenous use only and must never be given by the intrathecal route.

Myelosuppression

Leukopenia is the dose-limiting toxicity of Velvin. Regular monitoring of complete blood counts is required before each dose, and doses should be withheld or adjusted according to the WBC nadir and clinical status.

Peripheral neuropathy

Although less common than with vincristine, peripheral neuropathy (numbness, tingling, weakness, loss of reflexes) has been reported with Velvin and should be monitored during treatment; dose modification may be required if neurotoxicity develops.

Extravasation / local tissue injury

Velvin must be administered through a securely placed, well-functioning intravenous line. Extravasation can cause severe local tissue damage, cellulitis, and necrosis. If extravasation occurs, the injection should be stopped immediately and appropriate local management instituted according to institutional protocol.

Gastrointestinal effects

Constipation and, in severe cases, paralytic ileus may occur, particularly in elderly or debilitated patients; a prophylactic bowel regimen may be considered.

Other precautions

Velvin may cause jaw pain and hypertension in some patients. It requires administration and dose individualization by an oncology specialist familiar with vinca alkaloid protocols; it is not intended for outpatient self-administration. Bacterial infections should be treated before starting therapy, and patients should avoid contact with individuals who have recently received live vaccines.

Overdosage of Velvin may result in severe and prolonged bone marrow suppression, severe neurotoxicity, syndrome of inappropriate antidiuretic hormone secretion, paralytic ileus, and other serious toxicities, which can be fatal. There is no specific antidote.

Suspected overdose is a medical emergency - seek immediate medical attention or contact emergency services/a poison control center right away. Management involves supportive care, including monitoring and treatment of hematologic, gastrointestinal, and neurologic complications in a hospital setting; do not attempt home treatment.

Store Velvin in a refrigerator (2°C to 8°C), protected from light, unless the specific product's label states otherwise. Do not freeze. Keep out of reach of children. Handle and dispose of as a cytotoxic drug according to institutional guidelines.

Pediatric use: Velvin is used in children for specific indications such as Langerhans cell histiocytosis, under the direct supervision of a pediatric oncology specialist, with doses individualized by body surface area; safety and efficacy outside established pediatric oncology protocols have not been established.

Elderly: Elderly or debilitated patients may be more susceptible to constipation, paralytic ileus, and myelosuppression; closer monitoring and, where appropriate, dose adjustment may be needed.

Hepatic impairment: Dose reduction is recommended in patients with impaired hepatic function or elevated serum bilirubin, as Velvin is primarily eliminated via the liver and biliary system (see Dosage and Administration).

Renal impairment: No well-established dose adjustment is required for renal impairment alone, as renal elimination is minor; however, overall clinical status should be considered by the treating oncologist.

Pregnancy and lactation: See Pregnancy and Lactation section.

The duration of treatment with Velvin is determined by the treating oncologist based on the specific chemotherapy protocol, tumor response, and tolerance, typically continuing on a weekly or protocol-defined cycle for as many cycles as are indicated for the malignancy being treated, with ongoing monitoring of blood counts and clinical response.

Velvin for injection (lyophilized powder) should be reconstituted according to the manufacturer's instructions, typically using Sodium Chloride Injection (0.9%) to produce a solution of the labeled concentration; reconstituted solution should be inspected visually for particulate matter and discoloration prior to use, and used within the manufacturer-specified time when stored under refrigeration. If a ready-to-use liquid formulation is supplied, no reconstitution is required - follow the specific product's package insert.

Vinblastine Sulfate is classified as a Vinca alkaloid; Antineoplastic agent; Mitotic inhibitor (tubulin-binding cytotoxic chemotherapy drug).

Vinblastine Sulfate binds to tubulin dimers, inhibiting the polymerization of microtubules required for mitotic spindle formation. This arrests cell division in metaphase, ultimately leading to apoptosis of the cell, particularly in rapidly dividing malignant cells.

D

Velvin is used in pediatric patients for specific oncologic indications, such as Langerhans cell histiocytosis (Letterer-Siwe disease), only as part of an established pediatric oncology protocol under the direct supervision of a pediatric oncology specialist. Doses are individualized by body surface area, and safety/efficacy outside such specialist-directed protocols have not been established.